BCM-95® (CURCUGREEN®), 07 Aug 2021
Saeede Saadati, Amir Sadeghi, Asieh Mansour, Zahra Yari, Hossein Poustchi, Mehdi Hedayati, Behzad Hatami and Azita Hekmatdoost
Background: The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).
Methods: Fifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks.
Results: Curcumin supplementation was associated with significant decrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups (p < 0.05). None of the changes were significantly different between two groups.
Conclusion: Our results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation.
Trial registration: IRCT20100524004010N24, this trial was retrospectively registered on May 14, 2018.